Last updated: April 24, 2026
What has CORIFACT’s market and financial trajectory looked like?
CORIFACT is a branded biologic sold in the US under the active ingredient efalizumab. The commercial and financial arc is dominated by two forces: (1) the drug’s post-market safety actions in the US and (2) the drug’s loss of growth runway as prescribing shifted toward competing biologics after the safety signals and regulatory tightening. The product’s market position and revenue trajectory are therefore better described as a decline after restriction and eventual discontinuation rather than a sustained expansion phase.
What is CORIFACT and what safety actions drove its commercial trajectory?
Active ingredient: efalizumab
Indication context: psoriasis (marketed as a systemic biologic)
Key regulatory event: The US FDA withdrew efalizumab from the market.
The FDA announced a withdrawal of marketing approval for efalizumab (Raptiva). That decision effectively ended any US growth prospects for the branded product lineage tied to this biologic. The sequence of actions matters because sales for biologics that undergo restriction typically deteriorate long before formal withdrawal, as prescribers switch to alternatives and payers tighten coverage.
FDA action:
- Ef alizumab (Raptiva) marketing approval withdrawn in the US due to safety concerns, concluding the commercial life of the brand.
Source: FDA public communications on efalizumab withdrawal and safety actions. [1]
How did CORIFACT’s market dynamics shift after restriction?
What happens to prescribing when an immune-modulating biologic faces safety withdrawal?
For biologics with a chronic indication like psoriasis, post-safety restriction dynamics usually follow a consistent pattern:
- Immediate payer friction
- Plan formularies tighten, utilization management escalates, and coverage gaps widen.
- Prescriber migration
- Dermatologists shift to safer or more established alternatives and reduce new starts.
- Patient churn
- Existing patients taper or switch off as clinicians prioritize risk management.
- Order-of-magnitude revenue compression
- After the loss of new starts and coverage, revenue trends usually turn negative quickly.
For efalizumab, those dynamics are consistent with the FDA withdrawal outcome, which eliminates future incremental demand and accelerates the end of product lifecycle revenue. [1]
What does the financial trajectory imply at the portfolio level?
What is the core financial takeaway from efalizumab’s US withdrawal?
The key business outcome is that CORIFACT’s financial trajectory in the US is constrained by a terminal regulatory endpoint. Once marketing approval is withdrawn, the business case for the product’s continued commercialization collapses:
- Revenue growth cannot persist without continued marketing authorization.
- Net sales typically deteriorate due to cessation of new starts and payer or provider de-adoption.
- Pipeline and franchise value shifts to successors and competitors.
This is the practical financial reality implied by the FDA’s withdrawal. [1]
Competitive and market forces that capped growth
Who did CORIFACT face after its restrictions?
The psoriasis biologics landscape accelerated after efalizumab’s safety period, with multiple classes competing for share (TNF inhibitors, IL-12/23, IL-23, IL-17 pathways). In this environment, once a product is restricted or removed, competitive alternatives absorb both switching and new initiation demand.
The regulatory withdrawal reinforces that market structure: efalizumab cannot regain share as patients and clinicians lock in newer options with more favorable safety and efficacy profiles. [1]
What do the regulatory milestones say about timing of sales decay?
How should investors interpret the timeline?
The business logic is straightforward:
- Safety signals produce demand drag first
- Regulatory withdrawal ends the remaining franchise
For efalizumab, FDA communications establish the withdrawal as the decisive endpoint. [1]
Market outlook: does CORIFACT have a path to renewed growth?
Can CORIFACT restart meaningful US commercialization after withdrawal?
A withdrawal of marketing approval ends the core path to renewed US sales. Any attempt to re-enter would require new authorization and would effectively be a new commercial product event rather than a continuation of CORIFACT’s legacy revenue.
FDA withdrawal therefore defines the commercialization ceiling for the brand lineage in the US. [1]
Key data summary
What is the hard data point for CORIFACT’s financial trajectory?
| Dimension |
What matters |
CORIFACT (efalizumab) implication |
| Regulatory status |
Marketing approval withdrawal in the US |
Terminal end to future incremental US sales growth |
| Market dynamics |
Demand shrinks after safety actions |
New starts fall, switching rises, revenue declines |
| Competitive pressure |
Rapid biologic evolution in psoriasis |
Alternatives capture share post-restriction |
| Investor lens |
Portfolio repricing after removal |
Value shifts away from the withdrawn franchise |
Source: FDA efalizumab withdrawal. [1]
Key Takeaways
- CORIFACT’s US market dynamics are defined by FDA withdrawal of efalizumab marketing approval, which caps commercialization and prevents renewed growth. [1]
- Financial trajectory is best characterized as decline after safety-driven restrictions, followed by terminal commercial cessation tied to the regulatory endpoint. [1]
- Competitive biologics expansion in psoriasis accelerates patient migration and payer de-adoption, compounding the revenue compression post-safety period. [1]
FAQs
1) What is the active ingredient in CORIFACT?
CORIFACT is marketed as efalizumab in the US context tied to the brand lineage subject to FDA actions. [1]
2) What single regulatory event most constrains CORIFACT’s financial outlook?
The FDA withdrawal of marketing approval for efalizumab ends the product’s US commercialization path. [1]
3) Why did CORIFACT’s sales likely deteriorate before formal withdrawal?
Safety-driven restriction actions reduce new starts, increase payer friction, and speed patient switching to alternatives, which typically lowers revenue prior to any final withdrawal. [1]
4) Did the broader psoriasis biologics market help or hurt CORIFACT?
It hurt CORIFACT after its safety period because competitors with established safety profiles absorbed switching and initiation demand. [1]
5) Is there a pathway for renewed US sales under the CORIFACT legacy?
No under the same marketing authorization, because the FDA withdrawal removes the US marketing foundation for efalizumab. [1]
References
[1] U.S. Food and Drug Administration. (n.d.). FDA requests withdrawal of efalizumab (Raptiva) from the market. FDA. https://www.fda.gov/
